Company / Cash & Equivalents
AtriCure, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$167.4M
FY2025
5-year range
$43.7M / $167.4M
FY2021-FY2025
Trend
+36.4%
vs FY2024
Sector context
#92 of 152
Health Care
What the data says
At $167M, AtriCure, Inc.'s cash & equivalents ranks #92 of 152 in the Health Care sector. Cash & Equivalents has increased for 6 consecutive years, from $28M in FY2019 to $167M in FY2025.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of +31.9%.
Improved from $84M to $167M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +42.3%
- 5-Year CAGR
- +31.9%
- 10-Year CAGR
- -
Sector benchmark
#92 of 152 in Health CareTop 61% of 152This company $167.4M Sector average $1.2B
▼
-85.8% below sector average
Key checks
Key Insights
- AtriCure, Inc.'s cash & equivalents has grown for 6 consecutive years.
- 5-year CAGR of +31.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 36.4% year-over-year.
- Ranks #92 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -9.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.4M | +36.4% |
| FY2024 | $122.7M | +45.6% |
| FY2023 | $84.3M | +45.1% |
| FY2022 | $58.1M | +33.1% |
| FY2021 | $43.7M | +4.1% |
| FY2020 | $41.9M | +47.3% |
| FY2019 | $28.5M | -11.6% |
| FY2018 | $32.2M | +47.8% |
| FY2017 | $21.8M | -9.9% |
| FY2016 | $24.2M | +1.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026